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Background: Left ventricular (LV) longitudinal systolic dysfunction has been identified even in asymptomatic
patients with diabetes mellitus (DM) and preserved LV ejection fraction (LVEF). However, its relevant clinical features
have not been fully evaluated.
Methods: We studied 144 asymptomatic DM patients without coronary artery disease. Their mean age was
57 ± 15 years, 79 (55%) were female, and mean LVEF was 66 ± 4% (all ≥50%). Global longitudinal strain (GLS) was
determined as the average peak strain of 18 segments from the three standard apical views, and was expressed as
an absolute value. With the pre-defined cutoff for subclinical LV systolic dysfunction in DM patients with preserved
LVEF set at GLS < 18%, this dysfunction was detected in 53 patients (37%).
Results: Multivariate logistic regression analysis revealed that type 2 DM, hypertriglyceridemia, overweight/obesity,
nephropathy and neuropathy were independently associated with GLS < 18%, with nephropathy being the highest
risk factor (OR: 5.26; 95% CI 2.111-13.12, p < 0.001). For sequential logistic regression models, a model based on clinical
variables including gender, type 2 DM and DM duration (χ2 = 24.1) was improved by addition of overweight/obesity
and hypertriglyceridemia (χ2 = 45.6, p < 0.001), and further improved by addition of nephropathy and neuropathy
(χ2 = 70.2, p < 0.001) as variables. Furthermore, albuminuria significantly correlated with GLS (r = −0.51, p < 0.001),
and a multivariate regression model showed it to be the factor most closely associated with GLS (β = −0.33, p < 0.001).
Conclusions: Diabetic complications, hypertriglyceridemia and overweight/obesity were closely associated with
early stage of LV systolic longitudinal myocardial dysfunction in asymptomatic DM patients with preserved LVEF.
Our findings can be clinically noticeable for the management of DM patients.
Keywords: Diabetes mellitus, Nephropathy, Albuminuria, Echocardiography, Two-dimensional speckle-tracking
strain, Global longitudinal strainBackground
Diabetes mellitus (DM) is considered a major contribu-
tor of the development of heart failure (HF) despite ab-
sence of coronary artery disease and hypertension even
in patients with preserved left ventricular (LV) ejection
fraction (EF). This condition is known as diabetic cardio-
myopathy [1-3]. Although the pathogenesis of diabetic* Correspondence: tanakah@med.kobe-u.ac.jp
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unless otherwise stated.cardiomyopathy is believed to be multifactorial but with
the exact cause remaining unknown, a number of mecha-
nisms such as hyperglycemia and hyperinsulinemia have
been reported to play an important role in its etiology.
These changes are observed as changes in free acid me-
tabolism, increased apoptosis, activation of the renin-
angiotensin system, abnormalities in copper metabolism,
autonomic neuropathy, stem cell defect, and increased
oxidative stress among others. All these underlying patho-
genetic conditions change the cardiac structure and may
lead to cardiac fibrosis [1,4]. Diabetic cardiomyopathy is
currently defined as a diastolic dysfunction, and severalral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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function as the earliest functional alteration in the course
of diabetic cardiomyopathy [5-9], and also established it as
an important prognostic parameter [6]. On the other
hand, LV longitudinal myocardial systolic dysfunction
has been identified in DM patients with preserved LVEF
without overt coronary artery disease or HF [10-16]. In
addition, recent investigations have found that LV longi-
tudinal myocardial systolic dysfunction, rather than LV
diastolic dysfunction, should be considered the first
marker of a preclinical form of diabetic cardiomyopathy
in DM patients with preserved LVEF without overt HF
[14,17]. However, which characteristics of DM patients
are associated with impaired LV systolic longitudinal myo-
cardial function is not fully understood. Accordingly, our
objective was to evaluate the factors associated with the
clinical features of impaired LV longitudinal myocardial




A series of 150 consecutive DM patients including type
1 and type 2 DM who were admitted to Kobe University
Hospital between July 2013 and November 2014 were
prospectively recruited for this study. The diagnosis of
DM and its type were established according to the World
Health Organization criteria [18]. We excluded patients
with (1) ischemic heart disease; (2) LVEF < 50%; (3) a
previous history of open-heart surgery; (4) severe types
of renal dysfunction defined as glomerular filtration rate
(GFR) <30 mL/min/1.73 m2; (5) hypertension >180/
100 mmHg uncontrollable despite medical therapy; (6)
significant valvular heart disease; (7) atrial fibrillation;
and (8) left or right bundle branch block. All patients
underwent exercise stress testing such as treadmill exer-
cise or stress myocardial perfusion scintigraphy within
at least 2 weeks after admission, and none of the pa-
tients showed an ischemic response. Six initially eligible
patients (4%) were excluded from all subsequent analyses
because of suboptimal images from poor echocardio-
graphic windows. As a result, the final study group con-
sisted of 144 patients. The study protocol was approved
by the ethics committee of our institution and all patients
gave informed consent before participation.
Echocardiographic examination
All echocardiographic studies were performed using a com-
mercially available echocardiographic system within at least
2 weeks after admission (Vivid E9; GE-Vingmed, Horten,
Norway). Digital routine grayscale two-dimensional cine
loops from three consecutive heartbeats were obtained at
end-expiratory apnea from the standard parasternal long-
axis view and three apical views at depths of 12–14 cm andmean frame rates of 67 ± 8 frames/sec. Sector width was
optimized to allow for complete myocardial visualization
while maximizing the frame rate. Digital data were
transferred to dedicated software (EchoPAC version113;
GE Vingmed) for subsequent offline analysis. Standard
LV measurements were obtained in accordance with the
current guidelines of the American Society of Echocar-
diography/European Association of Cardiovascular Im-
aging [19]. LV volumes and LVEF were calculated using
the modified biplane Simpson’s method, which was also
employed to calculate left atrial volume using apical 2-
and 4-chamber views at the ventricular end-systole, and
then normalized to body surface area. LV mass was
indexed to both body surface area and height2.7, consider-
ing influence of obesity. LV stroke volume was determined
in terms of the velocity-time integral and assessed by
means of pulsed-wave Doppler positioned at the LV out-
flow tract. The early diastolic (E) and atrial wave velocities
and the E-wave deceleration time were measured using
pulsed-wave Doppler recording from the apical four-
chamber view. Spectral pulsed-wave Doppler-derived early
diastolic velocity (E’) was obtained from the septal mitral
annulus, and the E/E’ ratio was calculated to obtain an es-
timate of LV filling pressure [20].
Assessment of GLS
Speckle-tracking strain analysis was performed for each
patient with the aid of a single dedicated software (Echo-
PAC version 113; GE Vingmed). GLS was assessed by
means of two-dimensional speckle-tracking strain from
the three standard apical views as previously described
in detail. Briefly, a region of interest was traced on the
endocardium at end-systole with a point-and-click ap-
proach for each of the three apical views. A second lar-
ger region of interest was then generated and manually
adjusted near the epicardium. Apical images were di-
vided into six standard segments and six corresponding
time-strain curves were generated. GLS was determined
as the averaged peak strain of 18 segments from the
three standard apical views [19], and was expressed as
an absolute value (Figure 1). As previously detailed, the
pre-defined cutoff for subclinical LV systolic dysfunction
in DM patients with preserved LVEF was set at GLS <
18% [13-15,21].
Assessment of DM-related clinical features
Overweight/Obesity was defined as body mass index
(BMI) ≥25 kg/m2 according to World Health Organiza-
tion’s definition. Hypertension was defined as systolic
blood pressure ≥ 140 mmHg or diastolic blood pressure ≥
90 mmHg, or currently use of medication for hyperten-
sion [22]. Dyslipidemia was defined as fasting low-density
lipoprotein ≥ 140 mg/dl, or currently use of medication
for dyslipidemia [23]. Similarly, hypertriglyceridemia was
Figure 1 Example of color-coded 2-dimensional left ventricular (LV) display derived from the three standard apical views and corresponding peak
longitudinal strain values derived from 18 LV segments for measurement of global longitudinal strain (GLS). GLS was determined as the average
peak strain of the 18 LV segments, and was expressed as an absolute value.
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currently use of medication for hypertriglyceridemia [23].
Fasting hemoglobin A1c, 1,5-anhydroglucitol, glycoalbu-
min, creatinine, estimated glomerular filtration rate and
lipid profile were obtained on the day after admission. Al-
buminuria was determined on the basis of the average
measurement of albumin in urine collected over three 24-
hour periods. Nephropathy was defined as albuminuria at
least ≥30 mg/day (but GFR > 30 ml/min/1.73 m2) [24]. Ex-
perienced diabetologists assessed the presence of diabetic
neuropathy according to current guidelines and with ref-
erence to a nerve conduction study [25]. Moreover, dia-
betic retinopathy was defined when patients matched with
any one of following graduated classifications: microa-
neurysms only, mild-moderate, or severe non-proliferative
diabetic retinopathy, and proliferative diabetic retinopathy
or prior retinal photocoagulation by the experienced oph-
thalmologists [26].
Statistical analysis
Continuous variables were expressed as mean values and
standard deviation for normally distributed data and me-
dian and interquartile range for non-normally distrib-
uted data, while categorical variables were expressed as
frequencies and percentages. The parameters of the two
subgroups were compared by using Student t test or
Mann- Whitney U test as appropriate. Proportional
differences were evaluated with Fisher’s exact test. Rela-
tionships between two variables were analyzed by means
of linear regression and were expressed as Pearson
correlation coefficients. The associations of baseline
clinical parameters with reduced GLS were identified
by logistic regression in univariate and multivariateanalyses. Variables with p-values <0.10 were incorpo-
rated into the multivariate model by means of stepwise
selection. There was not multicollinearity between vari-
ables in the multivariate model. A sequential logistic
model for GLS < 18% was created to determine the in-
cremental enhancement of the prognostic value of the
patient’s characteristics including obesity, nephropathy,
and neuropathy compared to that of clinical variables in-
cluding age, gender and DM duration. A statistically sig-
nificant increase in the global log-likelihood χ2 of the
model was used to determine the incremental enhance-
ment of the prognostic value. The confounding factors for
logistic regression analysis and sequential logistic regres-
sion models were based on the associated factors with
subclinical LV dysfunctions in DM patients which were
previously reported. The inter-observer and intra-observer
variability of GLS was expressed as the absolute difference
between the measurements divided by their mean value
from 20 randomly selected patients. Albuminuria was
converted into a logarithmic scale according to its distri-
bution for each analysis. For all steps, a p value of < 0.05
was regarded as statistically significant. All analyses
were performed with SPSS version 16.0 (SPSS, Inc.,




The baseline clinical and echocardiographic characteristics
of the 144 DM patients are summarized in Table 1. Their
mean age was 57 ± 15 years, LVEF was 66 ± 4%, and 79 pa-
tients (55%) were female. The intra-observer variability was
3.8% and the inter-observer variability was 4.2% for GLS.
Table 1 Clinical, hemodynamic, and echocardiographic characteristics of patients
All patients (n = 144) Patients with
GLS ≥ 18% (n = 91)
Patients with
GLS < 18% (n = 53)
p value
Clinical Data
Age, years 57 ± 15 57 ± 15 57 ± 15 0.75
Female, n (%) 79(55) 55(60) 24(45) 0.09
Height, m 1.6 ± 1.0 1.6 ± 0.9 1.6 ± 1.0 0.20
Weight, kg 64 ± 15 60 ± 12 72 ± 18 <0.001
Body Mass Index, kg/m2 24.7 ± 4.9 23 ± 3.9 27 ± 6.0 <0.001
Systolic blood pressure, mmHg 124 ± 19 122 ± 17 130 ± 21 0.007
Diastolic blood pressure, mmHg 73 ± 11 71 ± 11 76 ± 10 0.002
Pulse pressure, mmHg 53 ± 15 51 ± 14 55 ± 17 0.03
Heart rate, bpm 69 ± 11 67 ± 11 71 ± 10 0.04
Rate Pressure Product, bpm*mmHg 9173 ± 1992 8741 ± 1812 9905 ± 2052 <0.001
Obesity, n (%) 58(40) 25(27) 33(62) <0.001
Type 2 DM, n (%) 104(72) 55(60) 49(92) <0.001
DM duration, years 11.8 ± 9.6 10.4 ± 8.4 13.6 ± 10.1 0.04
Hypertension, n (%) 69(48) 39(43) 30(57) 0.12
Dyslipidemia, n (%) 89(62) 53(58) 36(68) 0.29
Hypertriglyceridemia, n (%) 44(31) 17(19) 27(51) <0.001
Smoking, n (%) 31(22) 29(32) 25(47) 0.53
Complications
Nephropathy, n (%) 54(38) 13(14) 34(64) <0.001
Neuropathy, n (%) 47(33) 19(21) 29(55) <0.001
Retinopathy, n (%) 48(33) 29(32) 25(47) 0.07
Biochemistry and Urinary Examination
HbA1c, % 8.2(7.0-9.6) 8.0(6.8-9.0) 8.7(7.3-10.0) 0.21
1,5-anhydroglucitol, g/dl 4.3(2.4-8.1) 5.1(2.7-8.6) 3.3(2.0-7.1) 0.07
Glycoalbumin, % 21.8(17.4-27.2) 21.8(18.0-28.4) 22.0(16.8-26.8) 0.52
HOMA index 1.9(1.1-4.1) 1.5(1.0-3.0) 2.5(1.3-4.8) 0.049
Low-density lipoprotein, mg/dl 103 ± 35 100 ± 35 107 ± 34 0.22
High-density lipoprotein, mg/dl 53 ± 17 54 ± 16 50 ± 17 0.23
Triglyceride, mg/dl 112(78–159) 96(66–132) 154(113–203) <0.001
eGFR, ml/min/1.73 m2 77(61–89) 77(64–89) 74(58–90) 0.26
Albuminuria, mg/day 11.5(4.5-33.0) 7.0(3.0-18.0) 39.0(11.0-181.3) <0.001
Medications
Calcium channel blocker, n (%) 38(26) 21(23) 17(32) 0.25
ACEI/ARB, n (%) 58(40) 30(33) 28(53) 0.02
β-blocker, n (%) 13(9) 6(7) 7(13) 0.23
Diuretics, n (%) 10(7) 4(4) 6(11) 0.17
Statin, n (%) 68(47) 36(40) 32(60) 0.02
Insulin, n (%) 90(63) 58(64) 32(60) 0.72
DPP-4I, n (%) 55(38) 30(33) 25(47) 0.11
GLP-1RA, n (%) 13(9) 7(7) 6(11) 0.55
Sulfonylurea, n (%) 26(18) 15(16) 11(21) 051
α-GI, n (%) 26(18) 15(16) 11(21) 0.51
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Table 1 Clinical, hemodynamic, and echocardiographic characteristics of patients (Continued)
Thiazolidine, n (%) 13(9) 6(6) 7(13) 0.23
Metformin, n (%) 59(41) 31(34) 28(53) 0.04
Echocardiography
Relative wall thickness 0.45(0.39-0.51) 0.41(0.36-0.47) 0.49(0.47-0.60) <0.001
Left atrial volume index, ml/m2 28(22–34) 27(22–33) 31(23–37) 0.07
LV mass index, g/m2 75(63–86) 68(57–80) 83(74–94) <0.001
LV mass index, g/m2.7 34(27–41) 30(25–37) 41(33–46) <0.001
End-systolic volume, ml 26 ± 10 24 ± 9 29 ± 12 0.004
End-diastolic volume, ml 75 ± 22 71 ± 21 80 ± 23 0.004
LV ejection fraction, % 66 ± 4 67 ± 4 65 ± 5 0.002
Stroke volume, ml 62(56–72) 62(56–73) 63(56–69) 0.68
E/A 0.83(0.68-1.1) 0.86(0.7-1.2) 0.77(0.66-0.95) 0.03
E-wave deceleration time 189(163–227) 190(158–225) 187(167–235) 0.54
E’ 6.3(5.0-7.5) 6.5(5.6-8.1) 5.6(4.4-6.7) <0.001
E/E’ 9.6(8.0-11.6) 9.1(7.7-11.3) 10.3(9.1-13.5) 0.002
Global longitudinal strain, % 18.8 ± 2.7 20.4 ± 1.6 16.1 ± 1.7 <0.001
Values are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%).
DM = diabetes mellitus; HOMA = homeostatic model assessment; eGFR = estimated glomerular filtration rate; ACEI = angiotensin-converting enzyme inhibitor;
ARB = angiotensin II receptor blocker; DPP-4I = dipeptidyl peptidase-4 inhibitor; GLP-1RA = glucagon like peptide-1receptor agonist; α-GI = α-glucosidase inhibitor;
LV = left ventricular; E = peak early diastolic mitral flow velocity; A = peak late diastolic mitral flow velocity; E’ = Spectral pulsed-wave Doppler–derived early
diastolic velocity from the septal mitral annulus.
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GLS < 18% and ≥18%
Subclinical LV systolic dysfunction, defined as GLS < 18%,
was observed in 53 patients (37%), and the remaining 91
patients (63%) were classified as having preserved LV sys-
tolic function (Table 1). A comparison of the characteris-
tics of patients with GLS < 18% and those of patients with
GLS ≥ 18% showed that BMI, DM duration, fasting trigly-
ceride, albuminuria, systolic and diastolic blood pressures,
and rate pressure product were significantly larger than
for the latter group, whereas HbA1c, 1,5-anhydroglucitol,
and glycoalbumin, which indicates the degree of blood
sugar control in the recent phase, were similar for both
groups. In addition, prevalence of type 2 DM, over-
weight/obesity, nephropathy, neuropathy, and prescrip-
tion of angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers, statin and metformin
for patients with GLS < 18% were significantly higher
than for those with GLS ≥ 18%.
Comparison of echocardiographic parameters for patients
with GLS < 18% and ≥18%
The relative wall thickness, LV mass index, and LV vol-
umes of patients with GLS < 18% were significantly lar-
ger than those of patients with GLS ≥ 18%. In addition,
LVEF of patients with GLS < 18% was significantly lower,
and E/E’ for patients with GLS < 18% was significantly
higher than those of patients with GLS ≥ 18%. Finally,
the left atrial volume index (LAVI) for patients withGLS < 18% tended to be larger, but the difference was
not statistically significant.
Predictors of reduced GLS for DM patients
Univariate analysis using the logistic regression model
showed that type 2 DM and presence of overweight/
obesity, hypertriglyceridemia, nephropathy, neuropathy,
and retinopathy were associated with GLS < 18%. The
odds ratio (OR) and 95% confidence interval (CI) for
each of these variables are given in Table 2. An import-
ant finding of the multivariate logistic regression analysis
was that type 2 DM, overweight/obesity, hypertriglyc-
eridemia, nephropathy and neuropathy were independ-
ently associated with GLS < 18%, and nephropathy was
found to be the highest risk factor of GLS < 18% (OR:
5.26; 95% CI 2.111-13.12; p < 0.001). The incremental
advantage of using sequential logistic regression models
for the prediction of GLS < 18% is shown in Figure 2. A
model based on clinical variables including, gender, type
2 DM and DM duration (χ2 = 24.1) was improved by
addition of overweight/obesity and hypertriglyceridemia
(χ2 = 45.6, p < 0.001) and further improved by addition of
nephropathy and neuropathy (χ2 = 70.2, p < 0.001).
Association of clinical features with LV geometry and
function
The findings obtained with the multiple linear regression
analysis for association of clinical features with LV
geometry and function is shown in Table 3. Albuminuria
Table 2 Univariate and multivariate logistic regression analysis for detecting GLS < 18%
Univariate Multivariate
Dependent variables OR 95% CI p value OR 95% CI p value
Age 0.99 0.974-1.019 0.75
DM duration 1.03 0.996-1.069 0.08
Gender (female) 0.54 0.273-1.075 0.08
Type 2 DM 8.02 2.663-24.15 <0.001 5.39 1.329-21.86 0.02
Obesity 4.36 2.117-8.961 <0.001 2.96 1.201-7.312 0.02
Hypertension 1.74 0.878-3.446 0.11
Hypertriglyceridemia 4.52 2.128-9.604 0.001 3.43 1.347-8.739 0.001
Nephropathy 10.7 4.765-24.19 <0.001 5.26 2.111-13.12 <0.001
Neuropathy 4.58 2.184-9.600 <0.001 4.52 1.734-11.80 0.002
Retinopathy 2.21 1.105-4.439 0.02
GLS = global longitudinal strain; DM = diabetes mellitus; CI = confidence interval; OR = odds ratio.
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index (β = 0.27, p = 0.001) and GLS (β = −0.33, p <
0.001) even if adjusted for age, gender, DM duration,
and systolic blood pressure. Albuminuria was also one
of the independent determinative factors of E/E’ (β =
0.29, p = 0.001) together with age (β = 0.46, p < 0.001)
and female gender (β = 0.22, p = 0.004). In addition,
logarithmic albuminuria correlated negatively with GLS
(r = −0.51, p < 0.001) (Figure 3). Interestingly, triglyceride
correlated negatively with GLS (r = −0.41, p < 0.001), and
was also one of the independent contributing factors of
GLS (β = −0.24, p = 0.001), but low and high-density lipo-
protein were not.Figure 2 The incremental advantage of using sequential logistic
models for the prediction of GLS < 18%. A model based on
clinical variables including gender, type 2 diabetes mellitus (DM)
and DM duration (χ2 = 24.1) was improved by the addition of
hypertriglyceridemia and overweight /obesity (χ2 = 45.6; p < 0.001),
and further improved by the addition of nephropathy and
neuropathy (χ2 = 70.2; p < 0.001).Discussion
Comparison to other studies of the prevalence of subclinical
LV longitudinal systolic dysfunction in DM patients
This study confirms previous reports describing the sub-
clinical LV longitudinal systolic dysfunction in DM pa-
tients. Nakai et al. reported that GLS in DM patients
was significantly lower than that in age-matched normal
subjects despite of similar LVEF, and 43% (26/60) of DM
patients showed LV longitudinal systolic dysfunction de-
termined as GLS < 17.2%[10]. In addition, Ernande et al.
showed that 23% (36/154) of DM patients with pre-
served LVEF had LV longitudinal systolic dysfunction
determined as GLS < 18%[13]. Our study showed 37%
(53/144) of DM patients with preserved LVEF. Al-
though the prevalence of subclinical LV longitudinal
systolic dysfunction in DM patients with preserved
LVEF varied among studies, this may depend on the pa-
tient characteristics such as the severity of DM or DM-
related complications.
Subclinical LV longitudinal systolic dysfunction in DM
patients without overt HF
Pathophysiological causes of LV longitudinal dysfunction
in DM patients are microvasculopathy, myocardial hyper-
trophy and cardiac fibrosis [1]. The transforming growth
factor beta, aberrant differentiation of fibroblast progeni-
tor cells due to hyperinsulinemia, and dysregulation of
extracellular matrix due to hyperglycemia are also rec-
ognized as causes of not only renal but also cardiac fi-
brotic mechanism [27-29]. Ernande et al. prospectively
studied 154 asymptomatic DM patients with preserved
LVEF of ≥50% without overt heart disease to evaluate
the association of LV longitudinal function with LV re-
modeling [13]. They reported that LV remodeling had
progressed in patients with GLS < 18% at 3-year follow-
Table 3 Association of clinical features with LV geometry and function
Variable LV mass index Relative wall thickness LVEF E/E’ GLS
β p value β p value β p value β p value β p value
Age 0.28 <0.001 0.46 <0.001
DM duration
Gender (female) 0.17 0.012 0.22 0.004
Type 2 DM 0.28 <0.001
Body mass index 0.18 0.023 0.29 <0.001 −0.20 0.006
Systolic blood pressure 0.22 0.007 0.21 0.005
Triglyceride −0.24 0.001
Albuminuria 0.27 0.001 0.29 0.001 −0.33 <0.001
Neuropathy 0.15 0.039 −0.18 0.014
Retinopathy 0.18 0.016 0.20 0.012
Abbreviations as Table 1.
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was independently associated with changes in both LV
end-systolic and -diastolic volumes over the 3-year
period. Indeed, diabetic cardiomyopathy is currently de-
fined in terms of diastolic dysfunction, which is the
earliest functional alteration in the course of diabetic
cardiomyopathy [5-8]. However, LV diastolic dysfunction
has been established as an important prognostic param-
eter [6], while LV diastolic function is affected by many
other factors, such as age, hypertension, and LV hyper-
trophy. Ernande et al. also proved the presence of LV lon-
gitudinal dysfunction in DM patients with preserved LVEF
of ≥55%, as assessed by GLS, despite these patients’ nor-
mal diastolic function. This indicates that diastolic dys-
function should not be considered the first marker of a
preclinical form of diabetic cardiomyopathy [14].Figure 3 Dot plots of logarithmic albuminuria in relation to GLS
show a significant negative correlation.DM-related complications and LV longitudinal systolic
myocardial dysfunction
Our study established that diabetic nephropathy and
neuropathy were factors independently associated with LV
longitudinal systolic myocardial dysfunction in asymptom-
atic DM patients with preserved LVEF. In addition, ne-
phropathy had stronger influence on reduced GLS than
neuropathy in multivariate logistic regression. Close
cardio-renal connection can make us understood the
dominance of nephropathy [30]. Therefore, some previ-
ous investigators have focused on the interaction of al-
buminuria and LV functions in DM patients [30-35].
Moreover, albuminuria has been viewed as a mirror of
microvascular dysfunction, which results in vascular leak-
ing of not only albumin, collagen and cholesterol, but also
advanced glycation end products, and is the primary me-
diator of myocardial fibrosis due to the suppression of
collagen turnover via impaired crosslinking of collagen
[29,36]. Similarly, metabolic and vascular factors are in-
volved in the pathophysiology of diabetic peripheral neur-
opathy. Metabolic factors include increased deposition of
sorbitol, fructose, advanced glycation end products, and
free oxygen radicals that are produced by uncontrolled
hyperglycemia and cause painful damage to the peripheral
nerve. It was also found that hyperglycemia generates
microvascular ischemia, resulting in peripheral nerve
damage due to vasoconstriction and microvasculopathy
[37]. This phenomenon seems to be remarkably similar to
the pathogenic mechanism of diabetic cardiomyopathy.
On the other hand, among major DM-related complica-
tions only retinopathy was not an independent factor for
the detection of GLS < 18%. A previous study demon-
strated that deterioration of retinopathy is associated with
LV diastolic function [38], but its association with LV lon-
gitudinal systolic function remains indeterminate. In fact,
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between diabetic retinopathy and LV longitudinal systolic
function in 82 asymptomatic patients with type 2 DM and
preserved LVEF [39]. In this study, each retinopathy and
neuropathy independently and mildly correlated with DM
duration in multivariate model (r = 0.33, p = 0.001 and r =
0.19, p = 0.02), but nephropathy was not (p = 0.35). This
finding indicates that evaluating exact uncontrolled-DM
duration seems to be difficult and nephropathy may
have a possible of closely association with cardiac func-
tion over DM duration which was obtained just from
medical interview.
Overweight/obesity and hypertriglyceridemia were also
identified as two of the contributing factors of GLS in
our study, while other studies reported that obesity and
metabolic syndrome were harmful factors for LV subclin-
ical systolic and diastolic functioning [40-44]. Moreover,
obesity is considered to be associated with hypertriglyc-
eridemia, hyperinsulinemia, and insulin resistance [45-47].
Hypertriglyceridemia in particular is thought to be a cause
of myocardial steatosis, resulting in subclinical LV systolic
and diastolic dysfunction [48,49]. Our findings were thus
agree with those of previous studies.
Clinical implications
The pathogenesis of diabetic cardiomyopathy is consid-
ered to be multifactorial but the exact cause remains
unknown. As previously stated, LV longitudinal systolic
myocardial function could be a key parameter for the
development of HF or LV remodeling in asymptomatic
DM patients with preserved LVEF. However, what clin-
ical features of DM patients are associated with impaired
LV longitudinal systolic myocardial function has not
been fully investigated. Our findings indicate that the
highest risk factor of reduced GLS is diabetic nephropa-
thy, and that albuminuria is the most closely associated
with GLS. The detection of diabetic cardiomyopathy in
the early stages is important for the prevention of HF
that will develop in the future in asymptomatic DM pa-
tients with preserved LVEF. The new insights attained
by our study therefore suggest that early detection of
diabetic complications including diabetic nephropathy
and neuropathy is important for the maintenance of LV
longitudinal systolic function as well as the prevention
of overweight for asymptomatic DM patients, even though
their LVEF or LV diastolic function are preserved. It is
therefore advisable for medical specialists, especially dia-
betologists, to jointly plan assessment for better manage-
ment of DM patients.
Study limitations
This cross-sectional study covered a relatively small num-
ber of patients in a single center study, so that future stud-
ies of larger patient populations with longitudinal cohortdesign are necessary to assess our findings. Our study
populations included both type 1 (28%) and type 2 (72%)
DM patients. However, when we performed the analyses
for type 2 DM patients only, the overall results were simi-
lar. Finally, the confounding factors for logistic regression
analysis and sequential logistic regression models were
based on previously reported findings, so that a more
complete description for this analysis may necessary.
Conclusions
The assessment of diabetic complications, hypertriglyc-
eridemia overweight/obesity could prove to be important
for detecting of early stage of LV myocardial dysfunction
in asymptomatic DM patients despite preserved LVEF.
Our findings thus may well have clinical implications for
better management of DM patients.
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